Business Development

Amryt Pharma is focused on acquiring, developing and commercialising products to treat rare and orphan diseases.

Since its establishment in 2015, Amryt Pharma has acquired two products focused on Epidermolysis Bullosa and Acromegaly, in-licensed an EU-approved drug treatment for Homozygous Familial Hypercholesterolemia, Lojuxta® (lomitapide), as well an early-stage, novel gene therapy platform.

We remain focused on building-out our portfolio by in-licensing or acquiring innovative products to improve the lives of people living with rare and orphan diseases.

While we continue to focus on our core territories, we also aim to partner with companies in other regions for the distribution of our products.